(Q52874022)
Statements
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. (English)
Peter A Fasching
1 reference
Andreas Schneeweiss
1 reference
Sibylle Loibl
1 reference
Michael Untch
1 reference
Gunter von Minckwitz
Stefan Paepke
Annika Lehmann
Mahdi Rezai
Dirk M Zahm
Fariba Khandan
Holger Eidtmann
Karel Dohnal
Clemens Heinrichs
Jens Huober
Berit Pfitzner
Fabrice Andre
Judith L Lindner
Christos Sotiriou
August Dykgers
Sanxing Guo
Stephan Gade
Valentina Nekljudova
8 September 2014
32
29
3212-3220